Session » (2524–2546) Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

Date: Tuesday, October 28, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 2542

A Rule Based NLP Pipeline for Glucocorticoid exposure

10:30AM-12:30PM: Abstract Number: 2535

Behçet’s syndrome: distinct features in 344 pediatric and adult patients in a non-endemic region

10:30AM-12:30PM: Abstract Number: 2530

Broad Screening of Inflammation-Associated Proteins Identifies Serum CCL19 and CCL2 as Versatile Biomarkers of Disease Activity in IgG4-Related Disease

10:30AM-12:30PM: Abstract Number: 2528

Broad Screening of the Human Proteome Identifies a Cassette of Six Autoantigens that Distinguishes IgG4-Related Disease

10:30AM-12:30PM: Abstract Number: 2538

Comparative Study of Two Classification Criteria Sets in Real Clinical Practice in Behçet’s Disease

10:30AM-12:30PM: Abstract Number: 2531

Coronary periarteritis in IgG4-Related Disease

10:30AM-12:30PM: Abstract Number: 2541

Development of Severity Classification Criteria for Introduction of Infliximab for Chronic Pogressive Neuro-Behçet’s Disease

10:30AM-12:30PM: Abstract Number: 2546

Diagnostic Journey, Clinical Burden, And Quality Of Life Of Patients With IGg4-Related Disease: Results Of A Cross-Sectional Survey Of Patients And Physicians In The United States

10:30AM-12:30PM: Abstract Number: 2544

Diagnostic value of vein wall thickness measurement for patients with suspected Behçet syndrome

10:30AM-12:30PM: Abstract Number: 2534

Frequency of Ocular and Gastrointestinal Lesions Is Increased in Japanese Behçet’s Disease Patients with HLA-B61

10:30AM-12:30PM: Abstract Number: 2536

High Levels of Fatigue and Poor Sleep Quality in Behçet’s Disease: a Cross-sectional Study from a Non-endemic Area

10:30AM-12:30PM: Abstract Number: 2529

IgG4-Related Disease Paravertebral and Ureteropelvic Mass Presentations are Linked to Specific Disease Features

10:30AM-12:30PM: Abstract Number: 2526

Infection Risk Associated with Steroid-Sparing Therapies in GCA, PMR, and ANCA-Associated Vasculitis: A Systematic Review

10:30AM-12:30PM: Abstract Number: 2540

Monocyte-to-High-Density Lipoprotein Cholesterol Ratio as a Clinical Marker of Gastrointestinal Involvement in Behçet Syndrome

10:30AM-12:30PM: Abstract Number: 2539

Patient-reported outcomes in patients with polymyalgia rheumatica under rheumatology care: baseline data from the ENRICH-PMR cohort

10:30AM-12:30PM: Abstract Number: 2533

Patterns of skin lesion transcriptomics in different forms of vasculitis

10:30AM-12:30PM: Abstract Number: 2525

Point-of-Care Risk Factors for Systemic Disease in Patients Presenting with Small Vessel Vasculitis of the Skin

10:30AM-12:30PM: Abstract Number: 2545

Prevalence, Clinical Correlations and Outcomes of Cryoglobulinemic Vasculitis: a Retrospective Monocentric Study (2013–2023)

10:30AM-12:30PM: Abstract Number: 2524

Rituximab in the Treatment of Susac Syndrome: Single Center Descriptive Study with a Large Susac Cohort

10:30AM-12:30PM: Abstract Number: 2527

Safety Profile and Impaired Humoral Response to the Recombinant Herpes Zoster Vaccine in Behçet’s Syndrome Patients under Immunosuppression: a Prospective, Randomized, Placebo-Controlled Trial

10:30AM-12:30PM: Abstract Number: 2543

Severe Visual Impairment in Behçet Syndrome in Time: A Comparison of Four Time Periods

10:30AM-12:30PM: Abstract Number: 2532

Temporal arteritis revealing eosinophilic diseases: A multicenter retrospective study, literature review, and combined cluster analysis

10:30AM-12:30PM: Abstract Number: 2537

Variation in Treatment Approaches in IgA-Vasculitis Among Pediatricians and Pediatric rheumatologists: A Cross-Sectional International Survey

« View all sessions from this meeting